Phase II trial of docetaxel plus ramucirumab combination therapy in patients with advanced EGFR gene mutation positive advanced stage non-squamous cell nonsmall cell lung cancer (HSR 1701) - Phase II trial of docetaxel plus ramucirumab combination therapy in patients with advanced EGFR gene mutation positive advanced stage non-squamous cell nonsmall cell lung cancer (HSR 1701)

Second Division, Department of Internal Medicine, Hamamatsu university school of medicine0 个研究点目标入组 35 人开始时间: 2018年1月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Diagnosed as squamous cell carcinoma 2) History of hemoptysis(=>2.5mL) 3) Bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation 4) With thromboembolism 5) Peptic ulcer, gastrointestinal perforation, intestinal diverticulitis, inflammatory bowel disease combined 6) Tumor invasion in the blood vessel. 7) Symptomatic brain metastasis. 8) Exposure of the tumor to the central airway 9) With third-space fluid need to be drained. 10) Active double cancers within 5 years(cured intraepithelial carcinoma and intramucosal carcinoma are not included). 11) With severe complications Intestinal palsy, intestinal obstruction Interstitial pneumonia or pulmonary fibrosis Superior vena cava syndrome Difficult-to-control diabetes, hypertension, liver disorder, angina pectoris, congestive heart failure and myocardial infarction within 3 months after onset Cases with complications of severe infection or cases suspected of severe infection Cases with complications that are deemed to cause serious obstruction to treatment enforcement 12)Anticoaglation with aspirin (> 325 mg / day) or clopidogrel (> 75 mg / day). Prophylactic use of anticoagulants is acceptable). 13)Pregnant or breastfeeding women. Willing to get pregnant. Severe psychological disease 14)Judgment to attending physician.

发起方

Second Division, Department of Internal Medicine, Hamamatsu university school of medicine